Maze Therapeutics, INC

Maze Therapeutics announced the appointment of two seasoned biopharmaceutical executives, Paula Johnson and Sophie Kornowski, to its Board of Directors, bolstering its clinical and business expertise.

Maze Therapeutics announced its second quarter 2026 financial results, highlighting progress in its MZE829 and MZE782 clinical trials and a strong cash position extending runway into 2029.

Maze Therapeutics stockholders elected two Class I directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

Maze Therapeutics announced the resignation of Senior Vice President of Finance, Amy Bachrodt, effective June 1, 2026.

Maze Therapeutics announced positive topline data from its Phase 2 HORIZON trial for MZE829 in AMKD, alongside strong financial results and an extended cash runway into 2029.

Maze Therapeutics has priced a $150 million public offering of common stock and pre-funded warrants to extend its cash runway into 2029.

Maze Therapeutics Inc. announced its financial results for the second quarter of 2026, highlighting progress in its MZE829 and MZE782 clinical programs and a strong cash position.

Maze Therapeutics, Inc. announced its first quarter 2026 financial results, highlighting progress in its clinical-stage drug development programs and a strong cash position.

Maze Therapeutics reported a net loss of $30.1 million for Q3 2025, with increased R&D expenses, but maintains a strong cash position of $383.9 million following recent capital raises.

Maze Therapeutics reported a net loss of $33.7 million for Q2 2025, driven by increased R&D expenses for its lead clinical programs and the absence of 2024's one-time licensing revenue.

Maze Therapeutics reports a net loss of $32.8 million for Q1 2025, focusing on advancing its clinical programs MZE829 and MZE782.

Maze Therapeutics announced positive topline Phase 2 clinical data for MZE829 in kidney disease, alongside a significant net loss for 2025 and a new $200 million loan facility.

Maze Therapeutics reports a year of strategic shifts, marked by significant licensing agreements and progress in its clinical programs targeting renal and cardiovascular diseases.

Sophie Kornowski, a Director of Maze Therapeutics, Inc., received 36,000 shares of common stock on August 13, 2026.

Paula A Johnson, a Director of Maze Therapeutics, Inc., received 36,000 shares of common stock on August 13, 2026.

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., sold 16,142 shares of common stock on August 13, 2026 for $27.61 per share.

Atul Dandekar, CSBO of Maze Therapeutics, Inc., sold 7,500 shares of common stock on July 29, 2026.

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, reported transactions involving common stock and stock options on July 1, 2026.

Maze Therapeutics CEO Jason V. Coloma has sold a significant number of company shares through a pre-arranged trading plan.

Maze Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 8, 2026, to elect directors and ratify auditor appointment.

Maze Therapeutics, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of up to 9.2 million shares of common stock by existing selling stockholders.

Maze Therapeutics has filed a registration statement to increase the number of shares offered in its public offering by 1,092,500, including an underwriter option.

Maze Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to advance its pipeline of precision medicines for renal, cardiovascular, and metabolic diseases.

Maze Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to fund the development of its precision medicines for renal, cardiovascular, and metabolic diseases.

Maze Therapeutics, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an initial public offering to fund the development of its precision medicines targeting renal, cardiovascular, and metabolic diseases.

Paradigm BioCapital entities and Senai Asefaw have filed an amendment to their Schedule 13G, reporting no change in beneficial ownership of Maze Therapeutics common stock as of June 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 5.8% of Maze Therapeutics, Inc. common stock as of March 31, 2026.

Paradigm BioCapital Advisors LP and related entities have reported a 6.1% beneficial ownership stake in Maze Therapeutics, Inc. common stock.

Frazier Life Sciences Public Fund and affiliated entities disclose a combined 9.0% beneficial ownership in Maze Therapeutics, Inc. common stock.

Third Rock Ventures entities have reported a combined beneficial ownership of 11.3% in Maze Therapeutics, Inc. common stock.

Alphabet Inc. and its venture capital arm, GV, have disclosed a 2.9% beneficial ownership stake in Maze Therapeutics, Inc. through a Schedule 13G amendment.